Faced with a serious diagnosis or an unexpected hospitalization, patients and their families are often left feeling like they’ve been hit with a gut punch. This insecurity is compounded when the diagnosis is some type of rare condition, such as an uncommon sarcoma or an ailment that lacks widely accessible treatment like acute pancreatitis.
For those in the field of drug development, the desire to expedite the delivery and implementation of new treatments is tempered by an important but lengthy process created to ensure the efficacy and safety of any new protocol. These obstacles can feel like Sisyphean task when you acknowledge the decade-plus timeline and multi-billion dollar costs typically associated with bringing a new drug to market. That’s before we acknowledge the reality that 90 percent of drugs that enter clinical trials fail.
CLICK HERE to read Lamassu Biotech CEO Dr. Gabi Hanna’s column for Drug Discovery Online.